A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, SEAMLESS, ADAPTIVE,SAFETY, DOSE-FINDING, AND PHASE 3 CLINICAL STUDY OF UX701 AAV-MEDIATED GENE TRANSFER FOR THE TREATMENT OF WILSON DISEASE

Registry ID

UX701-CL301

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ULTRAGENYX PHARMACEUTICAL INC

Start date

2022-10-19

Last update

2021-12-03

Conditions

• WILSON'S DISEASE

View on source registry